Picard Medical is the parent of the only commercially approved total artificial heart in the United States and Canada, and the mid-year print shows that franchise finally covering kit cost while the holding company ran the cash account almost to zero. The investment debate is not whether SynCardia can implant devices at certified transplant centers. The debate is whether a one-product Tucson manufacturer can fund a public-company cost base, a next-generation platform, and an exchange-equity rebuild before the residual claim is diluted away. Management reported mid-year cash of $38 thousand. That figure is the entire equity story until a financing closes.
Second-quarter revenue rose 39 percent on stronger domestic kit sales, and product-level gross profit flipped from a prior-year loss into a positive print. That swing is the first clean evidence that SynCardia's fixed Tucson plant can cover device cost when United States centers actually order. The same quarter still produced an operating loss several times larger than gross profit because research spending and public-company overhead rose faster than kits. Half-year net loss also widened as debt-settlement charges and warrant marks overwhelmed the gross-profit turn. A single unnamed customer supplied most first-half revenue. Commercial progress is real and dangerously concentrated.
After quarter-end the company completed a one-for-fifty reverse split and NYSE American accepted an equity-standard compliance plan that runs into late 2027. Patrick Schnegelsberg left the chief executive role in June, and founder-chairman Richard Fang is running the company on an interim basis while a securities class action from the post-IPO trading window remains open. The next several months resolve a single question: can Picard raise enough capital, on terms that leave a residual claim, to keep SynCardia shipping while book equity climbs back above the exchange minimum?